← Back to Clinical Trials
Recruiting NCT04529122

A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

Trial Parameters

Condition Solid Tumours
Sponsor Hoffmann-La Roche
Study Type OBSERVATIONAL
Phase N/A
Enrollment 15,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-08-27
Completion 2027-12-31

Brief Summary

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

Eligibility Criteria

Inclusion Criteria: * Participant is an adult (according to the age of majority as defined by local regulations) * Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date) * Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results * Informed consent has been obtained from the participant or legally authorized representative, as per local regulations Exclusion Criteria: -Participant has a prior or current diagnosis of haematological malignancy

Related Trials